Compare Alcon AG (ALC) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Cassava Sciences Inc — how do they compare? Alcon AG trades at $74.19 (market cap $36.44B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Alcon AG is far larger — about 763.1× Cassava Sciences Inc's market cap, and Alcon AG pays a 0.48% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ALC | FLNA | |
|---|---|---|
Market Cap | $36.44B | $47.75M |
Sector | Health | Health |
52-Week High | $90.12 | $4.64 |
52-Week Low | $62.02 | $0.87 |
Enterprise Value | $40.28B | -$34.93M |
Dividend Yield | 0.48% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
